Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic hematopoietic stem cell transplantation.

Literature DB >> 15815047

Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic hematopoietic stem cell transplantation.

Michelle A Barron¹, Margaret Lay, Nancy E Madinger.

Abstract

This case report describes craniofacial zygomycosis in a 24-year-old male with Hodgkin's disease who underwent chemotherapy and autologous hematopoietic stem cell transplantation, followed by a nonmyeloablative allogeneic transplant. Empirical therapy with itraconazole and amoxicillin-clavulanate failed to resolve the infection. Postdiagnosis, surgery and treatment with high-dose liposomal amphotericin B eradicated the disease.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2005 PMID： 15815047 PMCID： PMC1081393 DOI： 10.1128/JCM.43.4.2012-2014.2005

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

13 in total

Review 1. Uncommon opportunistic fungi: new nosocomial threats.

Authors: A H Groll; T J Walsh
Journal: Clin Microbiol Infect Date: 2001 Impact factor: 8.067

2. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors: Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal: Clin Infect Dis Date: 2002-02-26 Impact factor: 9.079

Review 3. Newer antifungal therapy for emerging fungal pathogens.

Authors: William J Steinbach; John R Perfect
Journal: Int J Infect Dis Date: 2003-03 Impact factor: 3.623

4. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

Authors: Alexander Imhof; S Arunmozhi Balajee; David N Fredricks; Janet A Englund; Kieren A Marr
Journal: Clin Infect Dis Date: 2004-08-13 Impact factor: 9.079

5. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.

Authors: Francisco M Marty; Lisa A Cosimi; Lindsey R Baden
Journal: N Engl J Med Date: 2004-02-26 Impact factor: 91.245

6. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.

Authors: Qiu N Sun; Annette W Fothergill; Dora I McCarthy; Michael G Rinaldi; John R Graybill
Journal: Antimicrob Agents Chemother Date: 2002-05 Impact factor: 5.191

Review 7. Zygomycetes in human disease.

Authors: J A Ribes; C L Vanover-Sams; D J Baker
Journal: Clin Microbiol Rev Date: 2000-04 Impact factor: 26.132

8. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.

Authors: C B Miller; E K Waller; H G Klingemann; M C Dignani; E J Anaissie; P J Cagnoni; P McSweeney; P R Fleck; S M Fruchtman; J McGuirk; N J Chao
Journal: Bone Marrow Transplant Date: 2004-03 Impact factor: 5.483

9. Liposomal amphotericin B treatment for rhinocerebral mucormycosis: how much is enough?

Authors: Ophir Handzel; Zvi Landau; Doron Halperin
Journal: Rhinology Date: 2003-09 Impact factor: 3.681

Review 10. Zygomycosis.

Authors: Corina E Gonzalez; Michael G Rinaldi; Alan M Sugar
Journal: Infect Dis Clin North Am Date: 2002-12 Impact factor: 5.982

3 in total